475 Shares in IDEXX Laboratories, Inc. $IDXX Acquired by YHB Investment Advisors Inc.

Key Points

• YHB Investment Advisors Inc. acquired 475 shares of IDEXX Laboratories, Inc., valued at approximately $255,000, during the second quarter.
• Institutional investors own 87.84% of IDEXX's stock, indicating strong institutional interest in the company.
• IDEXX Laboratories reported $3.63 earnings per share for the last quarter, exceeding analysts' expectations and showing a 10.6% year-over-year revenue growth.

YHB Investment Advisors Inc. acquired a new position in IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 475 shares of the company's stock, valued at approximately $255,000.

Other institutional investors and hedge funds also recently made changes to their positions in the company. MorganRosel Wealth Management LLC purchased a new position in shares of IDEXX Laboratories in the first quarter worth approximately $26,000. Migdal Insurance & Financial Holdings Ltd. boosted its holdings in shares of IDEXX Laboratories by 55.6% in the first quarter. Migdal Insurance & Financial Holdings Ltd. now owns 84 shares of the company's stock worth $35,000 after buying an additional 30 shares during the last quarter. WPG Advisers LLC purchased a new position in shares of IDEXX Laboratories in the first quarter worth approximately $37,000. Bank of Jackson Hole Trust boosted its holdings in shares of IDEXX Laboratories by 328.6% in the first quarter. Bank of Jackson Hole Trust now owns 90 shares of the company's stock worth $39,000 after buying an additional 69 shares during the last quarter. Finally, Cornerstone Planning Group LLC boosted its holdings in shares of IDEXX Laboratories by 108.0% in the first quarter. Cornerstone Planning Group LLC now owns 104 shares of the company's stock worth $44,000 after buying an additional 54 shares during the last quarter. Hedge funds and other institutional investors own 87.84% of the company's stock.

Insider Activity

In related news, EVP Michael G. Erickson sold 406 shares of the business's stock in a transaction on Tuesday, August 12th. The shares were sold at an average price of $649.96, for a total value of $263,883.76. Following the sale, the executive vice president owned 11,287 shares in the company, valued at approximately $7,336,098.52. The trade was a 3.47% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Sharon E. Underberg sold 5,450 shares of the business's stock in a transaction on Friday, August 8th. The stock was sold at an average price of $651.60, for a total transaction of $3,551,220.00. Following the completion of the sale, the executive vice president owned 6,156 shares in the company, valued at $4,011,249.60. This represents a 46.96% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 54,057 shares of company stock valued at $34,293,468. Company insiders own 0.98% of the company's stock.

Wall Street Analyst Weigh In

IDXX has been the topic of a number of recent analyst reports. Stifel Nicolaus set a $640.00 target price on shares of IDEXX Laboratories in a research note on Monday, August 4th. Wall Street Zen upgraded shares of IDEXX Laboratories from a "buy" rating to a "strong-buy" rating in a research note on Saturday. Leerink Partners raised their target price on shares of IDEXX Laboratories from $580.00 to $600.00 and gave the stock an "outperform" rating in a research note on Thursday, July 17th. Piper Sandler restated a "neutral" rating and set a $700.00 target price (up previously from $510.00) on shares of IDEXX Laboratories in a research note on Monday, August 11th. Finally, Morgan Stanley raised their target price on shares of IDEXX Laboratories from $722.00 to $765.00 and gave the stock an "overweight" rating in a research note on Friday, August 15th. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and three have assigned a Hold rating to the company's stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $649.44.

IDEXX Laboratories Trading Up 0.1%

IDEXX Laboratories stock opened at $656.16 on Friday. The stock has a market cap of $52.49 billion, a P/E ratio of 54.63, a PEG ratio of 4.24 and a beta of 1.56. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.11 and a quick ratio of 0.79. IDEXX Laboratories, Inc. has a 1 year low of $356.14 and a 1 year high of $688.12. The firm's 50 day moving average price is $614.44 and its 200-day moving average price is $520.38.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last released its quarterly earnings data on Monday, August 4th. The company reported $3.63 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.28 by $0.35. The firm had revenue of $1.11 billion for the quarter, compared to analysts' expectations of $1.06 billion. IDEXX Laboratories had a net margin of 24.41% and a return on equity of 64.42%. The company's revenue for the quarter was up 10.6% compared to the same quarter last year. During the same quarter last year, the business posted $2.44 earnings per share. IDEXX Laboratories has set its FY 2025 guidance at 12.400-12.760 EPS. On average, equities analysts predict that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current fiscal year.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.